The researchers found that this treatment was beneficial in reducing pain while also improving quality of life. “Medical cannabis treatment with the Syqe Inhaler demonstrated overall long-term pain reductions, quality of life improvements, and opioid-sparing effects in a cohort of patients with chronic pain, using just a fraction of the amount of MC [medical cannabis] compared with other modes of delivery by inhalation. These outcomes were accompanied by a lower rate of AEs [adverse events] and almost no AE reports during a long-term steady-state follow-up. Additional follow-ups in a larger population is warranted to corroborate our findings,” the authors concluded.
Trulieve becomes the first U.S. cannabis company to trade on the NYSE on June 10.…
From robot canopy scanners to algorithmic breeders to AI-powered dispensary counters, artificial intelligence is remaking…
The latest version of this story comes from Virginia Commonwealth University, where researcher Emanuele Alves…
But there's more to this image than nostalgia and comedy. What you're looking at in…
The league pulled marijuana off its banned list in the new players’ agreement. In the…
In New South Wales, Australia, patients can legally use medical cannabis with a prescription. So…